- Company
- K-pharma trials show greenlight overcoming bile duct cancer
- by Son, Hyung Min Apr 4, 2025 05:58am
- South Korean and the overseas pharmaceutical industry's candidate products that are targeted anticancer agents for bile duct cancer (cholangiocarcinoma) are showing results of effectiveness, indicating the potential for commercialization possibilities. Korean and overseas pharmaceutical companies, including Handok's US partner Compass Therapeuti
- Company
- Obesity drug craze affects global pharma subsidiaries in KOR
- by Son, Hyung Min Apr 4, 2025 05:58am
- Whether or not a new obesity drug in the glucagon-like peptide (GLP-1) family has been launched has had a significant impact on the performance of Novo Nordisk and Lilly Korea. Last year, Novo Nordisk’s sales increased by 63% upon the launch of Wegovy in the domestic market. In the case of Lilly Korea, sales decreased slightly due to the delay
- Company
- New drug 'Niktimvo' for cGVHD receives ODD in Korea
- by Eo, Yun-Ho Apr 4, 2025 05:58am
- 'Niktimvo,' a new drug for the treatment of chronic graft-versus-host disease (cGVHD), has been designated as an orphan drug in South Korea. The Ministry of Food and Drug Safety (MFDS) announced this on the notifications of Orphan Drug Designation (ODD). Niktimvo (axatilimab)'s basis for ODD indication is for the treatment of 'adults an
- Company
- US postpones 'Drug Tariffs', but industry eyes the situation
- by Kim, Jin-Gu Apr 4, 2025 05:57am
- The US Trump administration announced reciprocal tariffs against the entire world, but “postponed” the application of tariffs on pharmaceuticals, because it is “considering separate industry-specific tariffs” on semiconductors, key minerals, and pharmaceuticals. The domestic pharmaceutical and bio industry is relieved for now but is
- Company
- Qarziba may be prescribed in general hospitals in KOR
- by Eo, Yun-Ho Apr 3, 2025 05:55am
- Qarziba, an immunotherapy drug that targets neuroblastoma, may now be prescribed at general hospitals in Korea. According to industry sources, Recordati Korea's immunotherapy drug for high-risk, recurrent, and refractory neuroblastoma, Qarziba Inj (dinutuximab beta), has passed the drug committees (DCs) of the ‘Big 5 general hospitals’
- Company
- "COVID-19 differs from influenza…vaccination essential"
- by Whang, byung-woo Apr 3, 2025 05:55am
- "COVID-19 can lead to 'long COVID,' and its progression tends to be more severe among the elderly and immunocompromised individuals. It is crucial to emphasize COVID-19 prevention as the saying goes, 'an ounce of prevention is worth a pound of cure.' After the announcement of the endemic in 2023, COVID-19 has repeatedly mutated, thus regarded
- Company
- J&J MedTech launches PFA Varipulse platform
- by Whang, byung-woo Apr 3, 2025 05:54am
- Johnson & Johnson MedTech announced on the 1st that it will launch the Varipulse platform, an arrhythmia treatment solution that uses three-dimensional pulsed field ablation (PFA), in Korea. As the most common arrhythmia in the world, Atrial fibrillation (AFib) is a condition in which the atria beat irregularly and rapidly. In particu
- Company
- ‘Leclaza combo will become the sole standard of care’
- by Son, Hyung Min Apr 3, 2025 05:54am
- &160;“The Leclaza + Rybrevant combination therapy has shown a clear improvement in survival compared to Tagrisso monotherapy in the MARIPOSA trial. I am confident that this combination therapy will become the sole standard treatment for EGFR-positive non-small cell lung cancer in the future.” On the 31st, Professor Byoung-chul Cho of t
- Company
- Korea's drug pricing system on US tariff on pharmaceuticals
- by Kim, Jin-Gu Apr 2, 2025 05:56am
- As the Trump administration's tariff against the world will go into effect immediately, a report has been released alleging that Korea's drug pricing and innovative pharmaceutical company certification policies are being unfairly imposed in the United States. According to the KoreaBIO on the 1st, the United States Trade Representative (US
- Company
- Olympus Korea appoints Tamai Takeshi as new head
- by Whang, byung-woo Apr 2, 2025 05:56am
- Olympus Korea, a global medical company, announced on April 1 that it has appointed Tamai Takeshi as its new Representative Director as of April 1. The new Representative Director Takeshi Tamai joined Olympus Korea in 2004 as a marketing manager in the medical business division and served as the General Manager of the medical division in
